Gemtuzumab ozogamicin (Mylotarg)

At a glance

Gemtuzumab ozogamicin (Mylotarg) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Liver monitoring and prompt action for infection or bleeding are especially important with Mylotarg. Treatment may be part of an intensive course that also includes other chemotherapy. Tell every treating team if a stem-cell transplant is planned or has already taken place, because this affects liver-risk assessment.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

Gemtuzumab recognises CD33, a protein found on certain blood cells. It carries a derivative of calicheamicin, a potent cell-killing substance that damages DNA, the cell’s genetic instructions. After entering a CD33-bearing cell, the payload can be released. The same process can affect healthy blood-cell production, contributing to infection and bleeding risks.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Gemtuzumab ozogamicin is used for selected CD33-positive acute myeloid leukaemia (AML). Its role depends on whether the AML is newly diagnosed or has returned, the patient’s age and the accompanying treatment. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

The team reviews CD33 testing, other laboratory and genetic findings, fitness for the proposed regimen, liver function and transplant history. CD33 positivity alone does not determine the full plan. Chromosome-risk findings also matter: benefit is less certain in adverse-risk AML, so the team reassesses the balance of benefit and harm when those results are available. Previous or planned stem-cell transplantation, significant liver disease and earlier gemtuzumab exposure must be considered together.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

Blood counts, liver tests, kidney function and blood salts are checked. Pregnancy testing is needed before treatment if you could become pregnant. The team may assess heart rhythm and review medicines that prolong the QT interval, a measurement on an ECG. A high circulating disease burden may require treatment before the infusion to reduce the risk of rapid cell breakdown. Baseline weight and examination of the abdomen help later assessment of fluid retention or liver enlargement.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

Mylotarg is infused over two hours. A commonly used adult combination schedule gives 3 mg/m² on days 1, 4 and 7 during induction with daunorubicin and cytarabine, followed by selected consolidation doses in patients whose plan calls for them. US information also contains single-agent schedules, and paediatric schedules differ. Product dose caps and vial presentations vary, so the prescription must be calculated by the specialist team. The schedule is not simply an indefinitely repeated three-weekly infusion.

A corticosteroid, antihistamine and paracetamol or acetaminophen are usually given before each dose to reduce infusion reactions. Monitoring continues during treatment and for at least one hour afterwards under US instructions. Severe allergic reactions, including anaphylaxis, require stopping the infusion and immediate treatment; the team determines permanent discontinuation according to the reaction and product instructions. Preventive fluids and a medicine to lower uric acid may be used to reduce tumour lysis risk. Hospital admission may be needed because of the complete regimen and the period of low blood counts.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

Platelet counts, other blood cells and liver tests are followed closely, including before each dose. US instructions specify blood counts and blood chemistry at least three times a week through recovery from treatment-related toxicity; follow the centre’s written schedule. Liver monitoring should not rely on bilirubin alone. The team looks for rapid weight gain, abdominal swelling, right-sided upper abdominal pain and other signs of liver blood-flow problems. Response assessment can include marrow examinations and detailed testing for remaining abnormal cells. The timing of any subsequent transplant requires specialist planning.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Bleeding, bruising and infection

Low platelets and low white cells can be substantial and prolonged, especially with intensive accompanying chemotherapy. Report new bruises, mouth bleeding, nosebleeds or infection symptoms promptly. Take preventive medicines exactly as prescribed and keep transfusion and blood-test appointments. Avoid rectal thermometers, suppositories or enemas unless specifically authorised when counts are low.

Mouth soreness, fever and digestive upset

Mouth ulcers, nausea, vomiting, diarrhoea or constipation can interfere with intake. Use the prescribed mouth-care and anti-sickness plan early. Fever may occur around treatment, but it cannot safely be assumed to be a harmless drug effect. During low counts, fever or sudden illness needs immediate assessment.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Liver sinusoidal obstruction syndrome

This serious complication is also called veno-occlusive disease, or VOD. Small blood vessels in the liver become obstructed, which can lead to liver enlargement, fluid retention and liver failure. It can occur during treatment, afterwards or around a subsequent stem-cell transplant. Report rapid weight gain, a swollen abdomen, pain under the right ribs, yellow eyes or reduced urine immediately. A normal bilirubin result alone does not exclude an evolving problem. Confirmed VOD requires stopping Mylotarg and specialist treatment.

Major bleeding

Very low platelets can cause dangerous bleeding, including internal bleeding. Blood in vomit, black or bloody stools, severe headache, new neurological symptoms or bleeding that will not stop requires urgent care. Follow platelet-transfusion and medication instructions carefully.

Tumour lysis and heart-rhythm problems

Rapid cell breakdown can alter potassium, phosphate, calcium and uric acid, putting the kidneys and heart at risk. Fluids and preventive medicines are tailored to your health; do not force excessive fluids if you have a restriction. Palpitations, fainting, severe weakness, cramps, confusion or reduced urine needs urgent assessment. Medicines that affect the QT interval and abnormal blood salts can add to rhythm risk.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review.

Other medicines and vaccinations

The team should check medicines that prolong the QT interval, affect the liver or increase bleeding, including some anti-sickness agents, antimicrobials and blood thinners. The complete chemotherapy regimen also has its own interactions. Transplant conditioning is a particularly important part of the treatment history because it can increase liver risk; do not treat it as unrelated to prior Mylotarg.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live vaccines require specific specialist advice. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

During periods of very low counts, the hospital may give additional food, dental and infection precautions. Ask before returning to contact sports or activities with a risk of falls or injury. If instructed to record daily weight, use the same scale at a similar time and report a rapid change rather than assuming it reflects improved eating.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment. US instructions specify at least six months after the final dose for a treated person who could become pregnant and at least three months for a treated man with a partner who could become pregnant. EU instructions specify two effective contraceptive methods and at least seven months for women or four months for men. Follow the plan agreed with your team for your product and full regimen. Do not breastfeed during treatment or for at least one month after the final dose.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Liver complications can develop after dosing has finished, including in connection with later transplantation. Keep the Mylotarg dates available to the transplant service and continue prescribed liver and blood-count monitoring. Recovery from the complete intensive course may take longer than recovery from an individual infusion.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions